热门资讯> 正文

XTL生物制药收到纳斯达克出价不足通知

2025-12-25 05:33

Xtl生物制药(XTLB) 0

XTL Biopharmaceuticals (XTLB) received a Nasdaq notice dated December 22, 2025, for failing to maintain the $1 minimum bid price requirement.
The deficiency is based on the company’s ADS closing bid price being below $1 for 30 consecutive business days.
XTL has a 180-day compliance period, ending June 22, 2026, to regain compliance.

More on XTL Biopharmaceuticals

Seeking Alpha’s Quant Rating on XTL Biopharmaceuticals
Financial information for XTL Biopharmaceuticals

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。